The first cell growth factor, nerve growth factor (NGF), was discovered by Rita Levi-Montalcini (RLM) 
INTRODUCTION
Rita Levi-Montalcini (RLM) was born April 22, 1909 in Turin, Italy, where received her medical degree from the University of Turin in 1936. The same year she entered the Institute of Anatomy as postgraduate student of Professor Giuseppe Levi, a well-known neuroanatomist and tutor of two other future Nobel Prize winners in Physiology or Medicine, Salvadore Luria (in 1969) and Renato Dulbecco (in 1975) . During her early postgraduate years, she studied the relationship between the developing nervous system and its peripheral targets and observed that many sensory neurons died during normal development, and that the limb bud extirpation caused an increase in the number of nerve cell death. The results of these studies
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lead her to the hypothesis that the failure of neurons to thrive in the absence of peripheral target was because of a degenerative process rather than a failure of differentiation, as had previously been hypothesized by Victor Hamburger, a well-known neuroembryologist working at the Department of Zoology, Washington University in St. Louis, MO. In 1946, Hamburger invited Levi-Montalcini to join his group to reinvestigate their scientific disagreements. In their initial published work LeviMontalcini and Hamburger (1951) prospected the hypothesis that the nerve-target interactions are reciprocally competitive in the sense that developing neurons depend on feedback (retrograde) signals from the peripheral tissues that are required for neuronal survival. These seminal observations and hypothesis pawed the way to the discovered of programmed cell death (in the today's context, the apoptosis), and later the discovery of nerve growth factor (NGF).
THE ROAD OF DISCOVERY
At the end of the nineteenth century, it was envisaged by Santiago Ramon y Cajal but has not been proven that life at the neuronal level requires trophic support. The proof was obtained by work initiated by Rita Levi-Montalcini in 1949. Then she first saw the results of Elmer Bueker, a former student of Hamburger, showing the effect of transplanting mouse sarcoma 180 into a chick embryo. Bueker observed that upon transplantation, the tumor stimulated the growth of fibers from neurons of the sensory ganglia into the tumor, just as they would have done into transplanted limbs and even more vigorously. He interpreted this result writing that the tumor transplantation effect was greater because the tumor provided a larger target area for the cells to expand than a limb would have. This interpretation did not convince Levi-Montalcini and following the suggestion of Hamburger then decided to repeat this experiment. She found the same result, but reached a different interpretation, hypothesizing that the transplanted tumor tissue induced hyperinnervation of internal chick organs by releasing a diffusible agent that stimulated the growth and differentiation of developing nerve cells. Using in vitro analysis, she studied the effect of this extract on isolated sensory and sympathetic nerve cells and clearly demonstrated the direct stimulating action of the tumor extract on nerve growth and named initially this yet unknown molecule nerve growth-stimulating factor, later termed NGF (Levi-Montalcini and Hamburger,1951; Levi-Montalcini 1952; Levi-Montalcini and Booker 1960). In attempt to purify the tumor-derived factor, Levi-Montalcini and Stanly Cohen used snake venom as a rich source of phosphodiesterase, a nucleic acid-destroying enzyme, for the separation of nucleic acids and protein fractions in the tumor material. To their great surprise, the tumor fraction containing the snake venom was several thousand-fold more potent than control tumor homogenate in promoting nerve growth, both in vitro and in vivo. Further on the road of discovery, LeviMontalcini and Cohen examined the mammalian homologue of the snake venom, the salivary gland, and found that the male mouse submandibular glands were an even richer source of the same nerve growth-stimulating activity found in both the tumor and the snake venom. Thus male mouse submandibular glands appeared to be a new and possibly largest source of NGF providing the possibility to isolate and purified consistent amount of this intriguing biomolecule. In effect, such an unpredictable experimental cascade (from tumor via snake venom to salivary glands) resulted in the discovery of NGF in 1951, a heuristic phenomenon marked by a rare combination of scientific reasoning, intuition, and chance.
THE NGF AND ITS RECEPTORS
Since its discovery, NGF becomes one of the best-characterized members of the protein family of neurotrophic factors designated neurotrophins, including NGF, BDNF, NT-3/4, NT-5, NT-6, and NT-7) (Aloe and Calzá, 2004). The biological action of NGF is mediated by (i) the high-affinity receptor TrkA (tropomyosin-related kinase receptor A; also known as tyrosine kinase receptor), and (ii) the low-affinity receptor termed p75 (pan)neurotrophin receptor (p75 NTR ).
In most cases, TrkA expression exerts protective actions on diseases involving degeneration of NGF target cells. In these diseases, the balance of TrkA and p75 NTR signaling pathways is altered through different mechanisms including co-receptor modulation. TrkA receptor agonists may provide alternatives in therapy of neurodegenerative and psychiatric diseases (see below). Of note, the NGF precursor proNGF induces apoptosis through p75 NTR (Fahnestock et al, 2004) .
NGF AND NON-NEURONAL CELLS
As often occurs, the framework of an initial conception of the physiological role of a newly discovered molecule extends in the light of emerging findings. This was also the case with NGF. 
THE THERAPEUTIC NGF
The treatment of diabetic polyneuropathy was one of earliest indication sought for clinical trial of NGF. The first results of these studies are at the moment controversial. Subsequent studies investigating the effect of NGF administration in rodent forebrain cholinergic neurons and behavior and memory performances lead to the hypothesis that NGF may be useful to protect these neurons that are known to degenerate in brain of subjects affected by Alzheimer's disease. While the therapeutic potential of NGF in the treatment of neurotrophic corneal ulcers, skin ulcers, glaucoma and Alzheimer's disease (Aloe et al, , 2012 seems clearly demonstrated, the use of NGF as drug is to some extend limited for its not fully established pharmacokinetics and the high cost associated with the production of human recombinant NGF. These obstacles have driven the scientific community also toward the identification of small molecules (NGF mimetics) with drug-like properties. These molecules may (i) directly bind to NGF receptors causing their activation, (ii) enhance the release of endogenous NGF, and/ or (iii) influence intracellular signaling pathways.
Several therapeutic strategies to delivery NGF in animal models and in human diseases have been explored and clinical steps have been attempted, while others are currently in progress to evaluate whether NGF and/or TrkA receptor agonists can prevent or protect against cell degeneration in the nervous system, visual system, cutaneous and myocardial tissue (Yuen et Chaldakov, 2011) . Contrary, TrkA receptor antagonists emerged as novel drugs for prostate (Weeraratna et al, 2000) and breast (Romon et al, 2010) cancer, bladder syndromes (Ochodnický et al, 2011) and various pain conditions (Mantyh et al, 2011) . Intriguingly, NGF may contribute to romantic love (Emanuele et al, 2006; Emanuele, 2011) .
The experimental approach also includes recombinant human neurotrophin application, direct gene transfer using (non-) viral vectors, the implantation of ex vivo genetically engineered cells secreting neurotrophic factors, and the grafting of neural stem progenitor cells. Every second years, experts in the field of NGF and other neurotrophic factors organize an international scientific meeting in different countries.
THE QUEEN OF NEUROSCINECE
Rita Levi-Montalcini has published more than 200 scientific articles which contributed in depth to the excellence of modern neuroscience. She had an unlimited interest both in scientific and human activities and is a member of numerous national and international scientific academies. In 1968 she was elected member of the National Academy of Science of USA. In 1972 -member of the American Association of Art and Science. In 1986 she was awarded Albet Lasker Award for Basic Medical Research, a precursor of Nobel prize she received in 1986 (Photograph 1).
In 1974 she was the first woman elected member of the Pontifical Academy of Sciences of the Vatican. Then Dr Tom Woolsey, the George H. and Ethel R. Bishop Scholar in Neuroscience at the School of Medicine, said: "When Levi-Montalcini was appointed to the Pontifical Academy by Pope Paul VI, the protocol required her to kneel and kiss the Pope's hand. Rita said: "I simply stood and shook the Pope's hand." In her independence and determination, she was a model for all scientists". 
Chaldakov and Aloe

THE COLLABORATORS
During her long scientific life, numerous young and senior scientists worked in RLM's laboratory. Many of them collaborated with her with long and short periods but contributed very little to the NGF studies. Others like Enrico Alleva in Italy and Ralph Bradshaw in USA gave novel contributions to the to the NGF studies. However, reading The Saga of Nerve Growth Factor and her numerous scientific publications, one can come to the conclusion that she had three major collaborators, Stanley Cohen (1953 Cohen ( -1959 , Pietro Angeletti (1959 Angeletti ( -1970 , and Luigi Aloe (1968 Aloe ( -2010 . Stanley Cohen, a biochemist contributed to study the early biochemical properties of the tumor extract and was the first Homage to RLM to purify the NGF from the snake venom and from the mouse salivary gland and to produce the anti-NGF antibodies. He shared with Levi-Montalcini the Nobel Price in 1986 for the discovered the epidermal growth factor.
Pietro Angeletti, a pathologist with an excellent preparation in biochemistry, made a substantial contribution to the study of NGF purification and to analysis of the spectrum of action of NGF in the peripheral nervous system and of the mechanism of immunosympathecotomy during early postnatal life.
Luigi Aloe (LA) first met Rita Levi-Montalcini in April 1967, at the Instituto Superiore of Sanità in Rome for an interview, while she was observing under the microscope the effect of anti-NGF antibody administration on the superior cervical ganglia of mice. The interview lasted about 20 minutes and two weeks later she called him asking if he would accept to work in her Laboratory in the Department of Zoology of the Washington University in St. Louis, Missouri, USA, for 6 months to take care of raising cockroaches for her studies on the insect nervous system. Luigi Aloe accepted her proposal, thereafter the 6 months became 12, then two years and, consequently, over 40 years. He contributed to identification of new NGF target cells within and outside the nervous system, particularly in immune cells, endocrine system and adipose tissue (as described above in NGF AND NON-NEURONAL CELLS). In the last few years, LA, in collaboration with clinicians, discovered that NGF is an important therapeutic molecule for healing the corneal, pressure and diabetic ulcers, as well as degenerating retinal cells in glaucoma and maculopathy. This latter observation has proved to be useful also for LeviMontalcini herself who suffers of the latter ocular disorder.
In 
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RESULTS OF A DREAM
During his student life at the Medical University, Varna, Bulgaria, one of us (GNC) used to work four years (1962) (1963) (1964) (1965) (1966) as research associated at the Department of Pharmacology. It was that period of time when he -for the first time -met in libro Rita Levi-Montalcini, reading her first NGF articles.
Since then he has being infected by this talented molecule, and thought how to reach her Institute in Rome, Italy. Although some colleagues told him that it is very much difficult pursuit, he continued to believe in his dream. On its road, in 1997 he has applied for NATO Research Fellowship, which required acceptance letter by the host institution. Obviously, his dream asked Luigi Aloe about and he provided him with such a letter, and consequently awarded a fellowship allowing him appeared in the Institute of Neurobiology, CNR, Rome, in June 1998. During this first four months there as well as almost each year further on, he was honored of meeting in vivo many times Rita Levi-Montalcini.
